<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01958463</url>
  </required_header>
  <id_info>
    <org_study_id>TASMC-12-ZH-500-CTIL</org_study_id>
    <nct_id>NCT01958463</nct_id>
  </id_info>
  <brief_title>Transplantation of Fecal Microbiota for Clostridium Difficile Infection</brief_title>
  <official_title>Transplantation of Fecal Microbiota for Clostridium Difficile Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tel-Aviv Sourasky Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tel-Aviv Sourasky Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recent data have demonstrated beneficial health outcomes of microbiota transplantation for&#xD;
      the treatment of Clostridium Difficile infection.&#xD;
&#xD;
      The investigators propose testing whether fecal transplantation from a healthy donor can lead&#xD;
      to a recovery from Clostridium Difficile recurrent/treatment-resistant infection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Infections by Clostridium Difficile are common both in the community and among hospitalized&#xD;
      patients. It is mostly prevalent following an antibiotic treatment. In recent years the&#xD;
      investigators are witnessing an increase in severity, incidence and treatment-resistant&#xD;
      cases.&#xD;
&#xD;
      Treatment-resistant infection or recurrent infection put the patient at risk for severe&#xD;
      complications, such as perforation, septic shock, megacolon and even death.&#xD;
&#xD;
      New antibiotic treatments such as Rifaximin and Fidaxomicin are not yet available for routine&#xD;
      use in Israel.&#xD;
&#xD;
      It is known that normal intestinal microbiota protect against Clostridium Difficile&#xD;
      infections, and as early as 1958, researchers have demonstrated that a transplantation of&#xD;
      fecal microbiota had a beneficial effect on Clostridium Difficile Infection.&#xD;
&#xD;
      In fact, previous data show that microbiota transplantation during colonoscopy, in patients&#xD;
      with treatment-resistant infection or recurrent infections, is an effective method with a 90%&#xD;
      success rate in a single treatment.&#xD;
&#xD;
      The investigators propose testing whether fecal transplantation from a healthy donor can lead&#xD;
      to a recovery from Clostridium Difficile infection.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical remission</measure>
    <time_frame>8 weeks after treatment</time_frame>
    <description>Less than 3 bowel movements a day</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Negative lab test for Clostridium Difficile</measure>
    <time_frame>8 weeks after treatment</time_frame>
    <description>No evidence for Clostridium Difficile in stool test.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Clostridium Difficile Infection</condition>
  <arm_group>
    <arm_group_label>Fecal microbiota transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fecal microbiota transplantation during colonoscopy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Fecal Microbiota transplantation.</intervention_name>
    <description>Fecal Microbiota transplantation during colonoscopy.</description>
    <arm_group_label>Fecal microbiota transplantation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age&gt;18 years.&#xD;
&#xD;
          -  A negative pregnancy test at inclusion, and a commitment to use contraception for a&#xD;
             period of six months from the date of transplant.&#xD;
&#xD;
          -  At least one of the following conditions :&#xD;
&#xD;
               1. An evidence of Clostridium infection recurrence within 6 months after completion&#xD;
                  of antibiotic course acceptable, which will include at least 10 days of treatment&#xD;
                  Bmtronidzol a total dose of 500 mg x3 per day and / or Bonkomitzin dose of at&#xD;
                  least 125 mg 4x a day .&#xD;
&#xD;
                  Recurrence of infection is defined clinical and laboratory :&#xD;
&#xD;
                    -  ≥ 3 diarrhea per day for at least two days in a row or ≥ 8 loose stools a&#xD;
                       day for 48 hours.&#xD;
&#xD;
                    -  a positive stool test for Clostridium Difficile toxin, or PCR / antigen&#xD;
                       detection.&#xD;
&#xD;
               2. First infection not responding to antibiotics (at least 10 days Metronidazole&#xD;
                  dosage of 1500 mg per day , or Bonkomitzin total dose of at least 500 mg per&#xD;
                  day).&#xD;
&#xD;
               3. A first infection in a patient who is intolerant or allergic to Lonkomitzin and&#xD;
                  metronidazole.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participation in another clinical study.&#xD;
&#xD;
          -  Inability to provide informed consent.&#xD;
&#xD;
          -  A pregnant woman or breastfeeding.&#xD;
&#xD;
          -  Severe neutropenia - below 500 neutrophils (blood counts).&#xD;
&#xD;
          -  A significant immunosuppression (SCID, CVID, GVHD, using different preparations&#xD;
             Aimonosofrsibiim , including prolonged corticosteroid therapy at doses equivalent to ≥&#xD;
             20 mg prednisone per day for more than 4 weeks).&#xD;
&#xD;
          -  Status of SIRS or hemodynamic/respiratory instability.&#xD;
&#xD;
          -  Toxic Megacolon, ischemic colitis, Fulminant colitis or a higher than usual risk of&#xD;
             colon perforatin during colonoscopy.&#xD;
&#xD;
          -  HBV infection or hepatitis C or HIV.&#xD;
&#xD;
          -  The use of antibiotics for the treatment of another disease at the time of inclusion.&#xD;
&#xD;
          -  A history of previous or current autoimmune disease, a progressive/an uncontrolled&#xD;
             disease of the kidney/liver/hematological system/endocrine system/ heart/neurological&#xD;
             system, or a metabolic disease.&#xD;
&#xD;
          -  An addiction to alcohol or drugs.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zmir Halpern, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tel-Aviv Sourasky Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zamir Halpern, MD</last_name>
    <phone>972-36974282</phone>
    <email>halpernza@tlvmc.gov.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Gastroenterology Institute</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
    <contact>
      <last_name>Noya Horowitz, PhD</last_name>
      <phone>972-3-6974297</phone>
      <email>noyah@tlvmc.gov.il</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <study_first_submitted>October 6, 2013</study_first_submitted>
  <study_first_submitted_qc>October 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 9, 2013</study_first_posted>
  <last_update_submitted>October 8, 2013</last_update_submitted>
  <last_update_submitted_qc>October 8, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 9, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Clostridium Difficile Infection</keyword>
  <keyword>Fecal Microbiota Transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Clostridium Infections</mesh_term>
    <mesh_term>Enterocolitis, Pseudomembranous</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

